The weekly litigation news digest is live. Subscribe now
Combinations Comprising Brexpiprazole Or A Salt Thereof And A Second Drug For Use In The Treatment Of A Cns Disorder - EP2694043
The patent EP2694043 was granted to Otsuka Pharmaceutical on Nov 1, 2017. The application was originally filed on Apr 4, 2012 under application number EP12719460A. The patent is currently recorded with a legal status of "Revoked".
EP2694043
- Application Number
- EP12719460A
- Filing Date
- Apr 4, 2012
- Status
- Revoked
- Feb 21, 2020
- Publication Date
- Nov 1, 2017
- External Links
- Slate, Register, Google Patents
Patent Summary
Combining the drug 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one (Compound (I)) with selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) to improve antidepressant efficacy and reduce side effects compared to monotherapy with either drug. The combination targets multiple neurotransmitter systems for more comprehensive antidepressant action. It also enables lower dosing frequency due to sustained release properties of Compound (I).
Patent Family
Patent Oppositions (2)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (13) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents